Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.

There are early-phase data with pembrolizumab (Keytruda) and epacadostat showing that adding the IDO inhibitor improved the response rate to pembrolizumab monotherapy from 40% to 55%, explains Luke. There was no increased toxicity observed in this combination.

A phase III trial investigating this combination compared with a placebo-controlled pembrolizumab monotherapy has completed accrual. According to Luke, this combination could change the standard of care for patients with melanoma.

View more from the World Congress of Melanoma

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Immunotherapy in Melanoma

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Melanoma & Skin Cancer

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Luke Discusses PD-1 Plus IDO Inhibitors in Melanoma